Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
John Byrd
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Concepts & Ideas
Procedures
Anatomy
Living Beings
Physiology
Sign-in to see full Profile
Network (preview)
63
Grever, Michael
30
Lin, Thomas
29
Lucas, David
29
Marcucci, Guido
22
Flinn, Ian
18
Johnson, Amy
16
Caligiuri, Michael
15
Heerema, Nyla
14
Muthusamy, Natarajan
13
Larson, Richard
13
Blum, William
12
Bloomfield, Clara
11
Lozanski, Gerard
11
Plass, Christoph
10
Liu, Shujun
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of John Byrd (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Hamadani Mehdi; Blum William; Phillips Gary; Elder Patrick; Andritsos Leslie; Hofmeister Craig; O'Donnell Lynn; Klisovic Rebecca; Penza Sam; Garzon Ramiro; Krugh David; Lin Thomas; Bechtel Thomas; Benson Don M; Byrd John C; Marcucci Guido; Devine Steven M
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(11):1422-30.
-
2009: Blum Kristie A; Advani Anjani; Fernandez Louis; Van Der Jagt Richard; Brandwein Joseph; Kambhampati Suman; Kassis Jeannine; Davis Melanie; Bonfils Claire; Dubay Marja; Dumouchel Julie; Drouin Michel; Lucas David M; Martell Robert E; Byrd John C
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.
British journal of haematology 2009;147(4):507-14.
-
2009: Byrd John C; Byrd John C; Peterson Bercedis L; Rai Kanti R; Byrd John C; Peterson Bercedis L; Rai Kanti R; Hurd David; Hohl Raymond; Perry Michael C; Gockerman Jon; Nattam Sreenivasa; Larson Richard A
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
Leukemia & lymphoma 2009;50(10):1589-96.
-
2009: Shanafelt Tait D; Byrd John C; LaPLant Betsy; Zent Clive S; Call Tim; Secreto Charla; Grever Michael R; Lin Thomas S; Kay Neil E
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
British journal of haematology 2009;146(6):660-4.
-
2009: Chen Shih-Shih; Raval Aparna; Johnson Amy J; Hertlein Erin; Liu Te-Hui; Jin Victor X; Sherman Mara H; Liu Shu-Jun; Dawson David W; Williams Katie E; Lanasa Mark; Liyanarachchi Sandya; Lin Thomas S; Marcucci Guido; Pekarsky Yuri; Davuluri Ramana; Croce Carlo M; Guttridge Denis C; Teitell Michael A; Byrd John C; Plass Christoph
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(32):13433-8.
-
2009: Woyach J A; Lin T S; Lucas M S; Heerema N; Moran M E; Cheney C; Lucas D M; Wei L; Caligiuri M A; Byrd J C
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(5):912-8.
-
2009: Lucas David M; Edwards Ryan B; Lozanski Gerard; West Derek A; Shin Jungook D; Vargo Melissa A; Davis Melanie E; Rozewski Darlene M; Johnson Amy J; Su Bao-Ning; Goettl Virginia M; Heerema Nyla A; Lin Thomas S; Lehman Amy; Zhang Xiaoli; Jarjoura David; Newman David J; Byrd John C; Kinghorn A Douglas; Grever Michael R
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
Blood 2009;113(19):4656-66.
-
2009: Blum Kristie A; Hamadani Mehdi; Phillips Gary S; Lozanski Gerard; Johnson Amy J; Lucas David M; Smith Lisa L; Baiocchi Robert; Lin Thomas S; Porcu Pierluigi; Devine Steven M; Byrd John C
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.
Leukemia & lymphoma 2009;50(3):349-56.
-
2009: Su Xiaodan; Lucas David M; Zhang Liwen; Xu Hua; Zabrouskov Vlad; Davis Melanie E; Knapp Amy R; Young Donn C; Payne Philip R O; Parthun Mark R; Marcucci Guido; Grever Michael R; Byrd John C; Freitas Michael A
Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.
Proteomics 2009;9(5):1197-206.
-
2009: Lapalombella Rosa; Gowda Aruna; Joshi Trupti; Mehter Najma; Cheney Carolyn; Lehman Amy; Chen Ching-Shih; Johnson Amy J; Caligiuri Michael A; Tridandapani Susheela; Muthusamy Natarajan; Byrd John C
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
British journal of haematology 2009;144(6):848-55.
-
2009: Phelps Mitch A; Lin Thomas S; Johnson Amy J; Hurh Eunju; Rozewski Darlene M; Farley Katherine L; Wu Di; Blum Kristie A; Fischer Beth; Mitchell Sarah M; Moran Mollie E; Brooker-McEldowney Michelle; Heerema Nyla A; Jarjoura David; Schaaf Larry J; Byrd John C; Grever Michael R; Dalton James T
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Blood 2009;113(12):2637-45.
-
2009: Yang Xiaojuan; Koh Chee Guan; Liu Shujun; Pan Xiaogang; Santhanam Ramasamy; Yu Bo; Peng Yong; Pang Jiuxia; Golan Sharon; Talmon Yeshayahu; Jin Yan; Muthusamy Natarajan; Byrd John C; Chan Kenneth K; Lee L James; Marcucci Guido; Lee Robert J
Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
Molecular pharmaceutics 2009;6(1):221-30.
-
2009: Awan Farrukh T; Kay Neil E; Davis Melanie E; Wu Wenting; Geyer Susan M; Leung Nelson; Jelinek Diane F; Tschumper Renee C; Secreto Charla R; Lin Thomas S; Grever Michael R; Shanafelt Tait D; Zent Clive S; Call Timothy G; Heerema Nyla A; Lozanski Gerard; Byrd John C; Lucas David M
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
Blood 2009;113(3):535-7.
-
2009: Fehniger Todd A; Byrd John C; Marcucci Guido; Abboud Camille N; Kefauver Cheryl; Payton Jacqueline E; Vij Ravi; Blum William
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
Blood 2009;113(5):1002-5.
-
2009: Yang Xiaojuan; Zhao Xiaobin; Phelps Mitch A; Piao Longzhu; Rozewski Darlene M; Liu Qing; Lee L James; Marcucci Guido; Grever Michael R; Byrd John C; Dalton James T; Lee Robert J
A novel liposomal formulation of flavopiridol.
International journal of pharmaceutics 2009;365(1-2):170-4.
-
2009: Christian Beth A; Grever Michael R; Byrd John C; Lin Thomas S
Flavopiridol in chronic lymphocytic leukemia: a concise review.
Clinical lymphoma & myeloma 2009;9 Suppl 3():S179-85.
-
2009: Joshi Trupti; Ganesan Latha P; Cheney Carolyn; Ostrowski Michael C; Muthusamy Natarajan; Byrd John C; Tridandapani Susheela
The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma.
PloS one 2009;4(1):e4208.
-
2008: Lapalombella Rosa; Yu Bo; Triantafillou Georgia; Liu Qing; Butchar Jonathan P; Lozanski Gerard; Ramanunni Asha; Smith Lisa L; Blum William; Andritsos Leslie; Wang Da-Sheng; Lehman Amy; Chen Ching-Shih; Johnson Amy J; Marcucci Guido; Lee Robert J; Lee L James; Tridandapani Susheela; Muthusamy Natarajan; Byrd John C
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
Blood 2008;112(13):5180-9.
-
2008: Trotta Rossana; Col Jessica Dal; Yu Jianhua; Ciarlariello David; Thomas Brittany; Zhang Xiaoli; Allard Jeffrey; Wei Min; Mao Hsiaoyin; Byrd John C; Perrotti Danilo; Caligiuri Michael A
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells.
Journal of immunology (Baltimore, Md. : 1950) 2008;181(6):3784-92.
-
2008: Klisovic Rebecca B; Blum William; Wei Xiaohui; Liu Shujun; Liu Zhongfa; Xie Zhiliang; Vukosavljevic Tamara; Kefauver Cheryl; Huynh Lenguyen; Pang Jiuxia; Zwiebel James A; Devine Steven; Byrd John C; Grever Michael R; Chan Kenneth; Marcucci Guido
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3889-95.
-
2008: Phelps Mitch A; Rozewski Darlene M; Johnston Jeffrey S; Farley Katherine L; Albanese Katie A; Byrd John C; Lin Thomas S; Grever Michael R; Dalton James T
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;868(1-2):110-5.
-
2008: Hertlein Erin; Byrd John C
CLL and activated NF-kappaB: living partnership.
Blood 2008;111(9):4427.
-
2008: Andritsos Leslie A; Johnson Amy J; Lozanski Gerard; Blum William; Kefauver Cheryl; Awan Farrukh; Smith Lisa L; Lapalombella Rosa; May Sarah E; Raymond Chelsey A; Wang Da-Sheng; Knight Robert D; Ruppert Amy S; Lehman Amy; Jarjoura David; Chen Ching-Shih; Byrd John C
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(15):2519-25.
-
2008: Gowda Aruna; Roda Julie; Hussain Syed-Rehan A; Ramanunni Asha; Joshi Trupti; Schmidt Susan; Zhang Xiaoli; Lehman Amy; Jarjoura David; Carson William E; Kindsvogel Wayne; Cheney Carolyn; Caligiuri Michael A; Tridandapani Susheela; Muthusamy Natarajan; Byrd John C
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
Blood 2008;111(9):4723-30.
-
2008: Klisovic Rebecca B; Stock Wendy; Cataland Spero; Klisovic Marko I; Liu Shujun; Blum William; Green Margaret; Odenike Olatoyosi; Godley Lucy; Burgt Jennifer Vanden; Van Laar Emily; Cullen Michael; Macleod A Robert; Besterman Jeffrey M; Reid Gregory K; Byrd John C; Marcucci Guido
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2444-9.
-
2008: Zhao Xiaobin; Wu Jianmei; Muthusamy Natarajan; Byrd John C; Lee Robert J
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.
Journal of pharmaceutical sciences 2008;97(4):1508-18.
-
2008: Hussain Syed-Rehan A; Lucas David M; Johnson Amy J; Lin Thomas S; Bakaletz Alan P; Dang Vinh X; Viatchenko-Karpinski Serge; Ruppert Amy S; Byrd John C; Kuppusamy Periannan; Crouser Elliott D; Grever Michael R
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.
Blood 2008;111(6):3190-9.
-
2008: Hung Jui-Hsiang; Lu Yen-Shen; Wang Yu-Chieh; Ma Yi-Hui; Wang Da-Sheng; Kulp Samuel K; Muthusamy Natarajan; Byrd John C; Cheng Ann-Lii; Chen Ching-Shih
FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling.
Cancer research 2008;68(4):1204-12.
-
2008: Liu Shujun; Liu Zhongfa; Xie Zhiliang; Pang Jiuxia; Yu Jianhua; Lehmann Esther; Huynh Lenguyen; Vukosavljevic Tamara; Takeki Mitsui; Klisovic Rebecca B; Baiocchi Robert A; Blum William; Porcu Pierluigi; Garzon Ramiro; Byrd John C; Perrotti Danilo; Caligiuri Michael A; Chan Kenneth K; Wu Lai-Chu; Marcucci Guido
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
Blood 2008;111(4):2364-73.
-
2008: Lapalombella Rosa; Zhao Xiaobin; Triantafillou Georgia; Yu Bo; Jin Yan; Lozanski Gerard; Cheney Carolyn; Heerema Nyla; Jarjoura David; Lehman Amy; Lee L James; Marcucci Guido; Lee Robert J; Caligiuri Michael A; Muthusamy Natarajan; Byrd John C
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):569-78.
-
2008: Liu Qing; Zhao Xiaobin; Frissora Frank; Ma Yihui; Santhanam Ramasamy; Jarjoura David; Lehman Amy; Perrotti Danilo; Chen Ching-Shih; Dalton James T; Muthusamy Natarajan; Byrd John C
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
Blood 2008;111(1):275-84.
-
2007: Blum Kristie A; Young Donn; Broering Sarah; Lucas Margaret S; Fischer Beth; Lin Thomas S; Grever Michael R; Byrd John C
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5624-9.
-
2007: Plass Christoph; Byrd John C; Raval Aparna; Tanner Stephan M; de la Chapelle Albert
Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes.
British journal of haematology 2007;139(5):744-52.
-
2007: Johnson Amy J; Wagner Amy J; Cheney Carolyn M; Smith Lisa L; Lucas David M; Guster Sara K; Grever Michael R; Lin Thomas S; Byrd John C
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
British journal of haematology 2007;139(5):837-44.
-
2007: Browning Rebekah L; Geyer Susan M; Johnson Amy J; Jelinek Diane F; Tschumper Renee C; Call Timothy G; Shanafelt Tait D; Zent Clive S; Bone Nancy D; Dewald Gordon W; Lin Thomas S; Heerema Nyla A; Grever Michael R; Kay Neil E; Byrd John C; Lucas David M
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.
Leukemia research 2007;31(12):1737-40.
-
2007: Christian Beth A; Grever Michael R; Byrd John C; Lin Thomas S
Flavopiridol in the treatment of chronic lymphocytic leukemia.
Current opinion in oncology 2007;19(6):573-8.
-
2007: Zhao Xiaobin; Lapalombella Rosa; Joshi Trupti; Cheney Carolyn; Gowda Aruna; Hayden-Ledbetter Martha S; Baum Peter R; Lin Thomas S; Jarjoura David; Lehman Amy; Kussewitt Donna; Lee Robert J; Caligiuri Michael A; Tridandapani Susheela; Muthusamy Natarajan; Byrd John C
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
Blood 2007;110(7):2569-77.
-
2007: Neviani Paolo; Santhanam Ramasamy; Oaks Joshua J; Eiring Anna M; Notari Mario; Blaser Bradley W; Liu Shujun; Trotta Rossana; Muthusamy Natarajan; Gambacorti-Passerini Carlo; Druker Brian J; Cortes Jorge; Marcucci Guido; Chen Ching-Shih; Verrills Nicole M; Roy Denis C; Caligiuri Michael A; Bloomfield Clara D; Byrd John C; Perrotti Danilo
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
The Journal of clinical investigation 2007;117(9):2408-21.
-
2007: Grever Michael R; Lucas David M; Johnson Amy J; Byrd John C
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.
Best practice & research. Clinical haematology 2007;20(3):545-56.
-
2007: Blum William; Klisovic Rebecca B; Hackanson Bjoern; Liu Zhongfa; Liu Shujun; Devine Hollie; Vukosavljevic Tamara; Huynh Lenguyen; Lozanski Gerard; Kefauver Cheryl; Plass Christoph; Devine Steven M; Heerema Nyla A; Murgo Anthony; Chan Kenneth K; Grever Michael R; Byrd John C; Marcucci Guido
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3884-91.
-
2007: Zhao Xiaobin B; Muthusamy Natarajan; Byrd John C; Lee Robert J
Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes.
Journal of pharmaceutical sciences 2007;96(9):2424-35.
-
2007: Byrd John C; O'Brien Susan; Flinn Ian W; Kipps Thomas J; Weiss Mark; Rai Kanti; Lin Thomas S; Woodworth James; Wynne Dee; Reid Jennifer; Molina Arturo; Leigh Bryan; Harris Sarah
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4448-55.
-
2007: Pal Sharmistha; Baiocchi Robert A; Byrd John C; Grever Michael R; Jacob Samson T; Sif Saïd
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
The EMBO journal 2007;26(15):3558-69.
-
2007: Ali Naeem A; O'Brien James M; Blum William; Byrd John C; Klisovic Rebecca B; Marcucci Guido; Phillips Gary; Marsh Clay B; Lemeshow Stanley; Grever Michael R
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.
Cancer 2007;110(1):96-102.
-
2007: Motiwala Tasneem; Majumder Sarmila; Kutay Huban; Smith David Spencer; Neuberg Donna S; Lucas David M; Byrd John C; Grever Michael; Jacob Samson T
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3174-81.
-
2007: Raval Aparna; Tanner Stephan M; Byrd John C; Angerman Elizabeth B; Perko James D; Chen Shih-Shih; Hackanson Björn; Grever Michael R; Lucas David M; Matkovic Jennifer J; Lin Thomas S; Kipps Thomas J; Murray Fiona; Weisenburger Dennis; Sanger Warren; Lynch Jane; Watson Patrice; Jansen Mary; Yoshinaga Yuko; Rosenquist Richard; de Jong Pieter J; Coggill Penny; Beck Stephan; Lynch Henry; de la Chapelle Albert; Plass Christoph
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.
Cell 2007;129(5):879-90.
-
2007: Shanafelt Tait D; Lin Thomas; Geyer Susan M; Zent Clive S; Leung Nelson; Kabat Brian; Bowen Deborah; Grever Michael R; Byrd John C; Kay Neil E
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
Cancer 2007;109(11):2291-8.
-
2007: Alinari L; Lapalombella R; Andritsos L; Baiocchi R A; Lin T S; Byrd J C
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Oncogene 2007;26(25):3644-53.
-
2007: Su Xiaodan; Jacob Naduparambil K; Amunugama Ravindra; Lucas David M; Knapp Amy R; Ren Chen; Davis Melanie E; Marcucci Guido; Parthun Mark R; Byrd John C; Fishel Richard; Freitas Michael A
Liquid chromatography mass spectrometry profiling of histones.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;850(1-2):440-54.
-
2007: Cheng Hao; Liu Zhongfa; Blum William; Byrd John C; Klisovic Rebecca; Grever Michael R; Marcucci Guido; Chan Kenneth K
Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;850(1-2):206-12.
-
2007: Hussain Syed-Rehan A; Cheney Carolyn M; Johnson Amy J; Lin Thomas S; Grever Michael R; Caligiuri Michael A; Lucas David M; Byrd John C
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2144-50.
-
2007: Su Xiaodan; Zhang Liwen; Lucas David M; Davis Melanie E; Knapp Amy R; Green-Church Kari B; Marcucci Guido; Parthun Mark R; Byrd John C; Freitas Michael A
Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.
Analytical biochemistry 2007;363(1):22-34.
-
2007: Knapp Amy R; Ren Chen; Su Xiaodan; Lucas David M; Byrd John C; Freitas Michael A; Parthun Mark R
Quantitative profiling of histone post-translational modifications by stable isotope labeling.
Methods (San Diego, Calif.) 2007;41(3):312-9.
-
2007: Grever Michael R; Lucas David M; Dewald Gordon W; Neuberg Donna S; Reed John C; Kitada Shinichi; Flinn Ian W; Tallman Martin S; Appelbaum Frederick R; Larson Richard A; Paietta Elisabeth; Jelinek Diane F; Gribben John G; Byrd John C
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):799-804.
-
2007: Kay Neil E; Geyer Susan M; Call Timothy G; Shanafelt Tait D; Zent Clive S; Jelinek Diane F; Tschumper Renee; Bone Nancy D; Dewald Gordon W; Lin Thomas S; Heerema Nyla A; Smith Lisa; Grever Michael R; Byrd John C
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
Blood 2007;109(2):405-11.
-
2007: Byrd John C; Lin Thomas S; Dalton James T; Wu Di; Phelps Mitch A; Fischer Beth; Moran Mollie; Blum Kristie A; Rovin Brad; Brooker-McEldowney Michelle; Broering Sarah; Schaaf Larry J; Johnson Amy J; Lucas David M; Heerema Nyla A; Lozanski Gerard; Young Donn C; Suarez Jose-Ramon; Colevas A Dimitrios; Grever Michael R
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Blood 2007;109(2):399-404.
-
2006: Khan Khuda D; Emmanouilides Christos; Benson Don M; Hurst Deborah; Garcia Pablo; Michelson Glenn; Milan Sandra; Ferketich Amy K; Piro Lawrence; Leonard John P; Porcu Pierluigi; Eisenbeis Charles F; Banks Amy L; Chen Lei; Byrd John C; Caligiuri Michael A
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7046-53.
-
2006: Blum Kristie A; Johnson Jeffrey L; Niedzwiecki Donna; Piro Lawrence D; Saven Alan; Peterson Bruce A; Byrd John C; Cheson Bruce D;
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
Cancer 2006;107(12):2817-25.
-
2006: Shanafelt Tait D; Byrd John C; Call Timothy G; Zent Clive S; Kay Neil E
Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.
Annals of internal medicine 2006;145(6):435-47.
-
2006: Johnson Amy J; Lucas David M; Muthusamy Natarajan; Smith Lisa L; Edwards Ryan B; De Lay Michael D; Croce Carlo M; Grever Michael R; Byrd John C
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
Blood 2006;108(4):1334-8.
-
2006: Gowda Aruna; Byrd John C
Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia.
Current opinion in hematology 2006;13(4):266-72.
-
2006: Ganesan Latha P; Joshi Trupti; Fang Huiqing; Kutala Vijay Kumar; Roda Julie; Trotta Rossana; Lehman Amy; Kuppusamy Periannan; Byrd John C; Carson William E; Caligiuri Michael A; Tridandapani Susheela
FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways.
Blood 2006;108(2):718-25.
-
2006: Wittstein Jocelyn R; Bartlett Edwin C; Easterbrook James; Byrd James C
Magnetic resonance imaging evaluation of patellofemoral malalignment.
Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association 2006;22(6):643-9.
-
2006: Willis Carl R; Goodrich Amy; Park Kathy; Waselenko Jamie K; Lucas Margaret; Reese Amy; Diehl Louis F; Grever Michael R; Byrd John C; Flinn Ian W
A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Annals of hematology 2006;85(5):301-7.
-
2006: Byrd John C; Lin Thomas S; Grever Michael R
Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
Seminars in oncology 2006;33(2):210-9.
-
2006: Raval Aparna; Byrd John C; Plass Christoph
Epigenetics in chronic lymphocytic leukemia.
Seminars in oncology 2006;33(2):157-66.
-
2006: Chen Hui-Chen; Byrd John C; Muthusamy Natarajan
Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(4):2208-18.
-
2006: Mone A P; Cheney C; Banks A L; Tridandapani S; Mehter N; Guster S; Lin T; Eisenbeis C F; Young D C; Byrd J C
Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(2):272-9.
-
2006: Liu Te-Hui; Raval Aparna; Chen Shih-Shih; Matkovic Jennifer J; Byrd John C; Plass Christoph
CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia.
Cancer research 2006;66(2):653-8.
-
2006: Blum William; Bolwell Brian J; Phillips Gary; Farag Sherif S; Lin Thomas S; Avalos Belinda R; Penza Sam L; Marcucci Guido; Byrd John C; Kalaycio Matt E; Sobecks Ronald M; Pohlman Brad; Brown Stacey; Elder Patrick J; Copelan Edward A
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(1):61-7.
-
2006: Byrd John C; Gribben John G; Peterson Bercedis L; Grever Michael R; Lozanski Gerard; Lucas David M; Lampson Ben; Larson Richard A; Caligiuri Michael A; Heerema Nyla A
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):437-43.
-
2006: Liu Zhongfa; Marcucci Guido; Byrd John C; Grever Michael; Xiao Jim; Chan Kenneth K
Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method.
Rapid communications in mass spectrometry : RCM 2006;20(7):1117-26.
-
2006: Brena Romulo Martin; Auer Herbert; Kornacker Karl; Hackanson Björn; Raval Aparna; Byrd John C; Plass Christoph
Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform.
Nucleic acids research 2006;34(3):e17.
-
2005: Kasamon Yvette L; Flinn Ian W; Grever Michael R; Diehl Louis F; Garrett-Mayer Elizabeth; Goodman Steven N; Lucas Margaret S; Byrd John C
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8413-7.
-
2005: Mone Andrew; Puhalla Shannon; Whitman Susan; Baiocchi Robert A; Cruz Julio; Vukosavljevic Tamara; Banks Amy; Eisenbeis Charles F; Byrd John C; Caligiuri Michael A; Porcu Pierluigi
Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.
Blood 2005;106(10):3380-2.
-
2005: Flinn Ian W; Byrd John C; Bartlett Nancy; Kipps Thomas; Gribben John; Thomas Deborah; Larson Richard A; Rai Kanti; Petric Rosemary; Ramon-Suerez Jose; Gabrilove Janice; Grever Michael R
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
Leukemia research 2005;29(11):1253-7.
-
2005: Lin T S; Flinn I W; Lucas M S; Porcu P; Sickler J; Moran M E; Lucas D M; Heerema N A; Grever M R; Byrd J C
Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(7):1207-10.
-
2005: Byrd John C; Peterson Bercedis L; Gabrilove Janice; Odenike Olatoyosi M; Grever Michael R; Rai Kanti; Larson Richard A;
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4176-81.
-
2005: Raval Aparna; Lucas David M; Matkovic Jennifer J; Bennett Kristi L; Liyanarachchi Sandya; Young Donn C; Rassenti Laura; Kipps Thomas J; Grever Michael R; Byrd John C; Plass Christoph
TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3877-85.
-
2005: Kreiling Jodi L; Byrd James C; MacDonald Richard G
Domain interactions of the mannose 6-phosphate/insulin-like growth factor II receptor.
The Journal of biological chemistry 2005;280(22):21067-77.
-
2005: Marcucci Guido; Stock Wendy; Dai Guowei; Klisovic Rebecca B; Liu Shujun; Klisovic Marko I; Blum William; Kefauver Cheryl; Sher Dorie A; Green Margaret; Moran Mollie; Maharry Kati; Novick Steven; Bloomfield Clara D; Zwiebel James A; Larson Richard A; Grever Michael R; Chan Kenneth K; Byrd John C
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3404-11.
-
2005: Tseng Ping-Hui; Lin Ho-Pi; Zhu Jiuxiang; Chen Kuen-Feng; Hade Erinn M; Young Donn C; Byrd John C; Grever Michael; Johnson Kara; Druker Brian J; Chen Ching-Shih
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Blood 2005;105(10):4021-7.
-
2005: Bolaños-Meade Javier; Jacobsohn David A; Margolis Jeffrey; Ogden Adam; Wientjes M Guillaume; Byrd John C; Lucas David M; Anders Viki; Phelps Michele; Grever Michael R; Vogelsang Georgia B
Pentostatin in steroid-refractory acute graft-versus-host disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2661-8.
-
2005: Jenkins Lisa M Miller; Byrd J Calvin; Hara Toshiaki; Srivastava Pratibha; Mazur Sharlyn J; Stahl Stephen J; Inman John K; Appella Ettore; Omichinski James G; Legault Pascale
Studies on the mechanism of inactivation of the HIV-1 nucleocapsid protein NCp7 with 2-mercaptobenzamide thioesters.
Journal of medicinal chemistry 2005;48(8):2847-58.
-
2005: Lin T S; Penza S L; Avalos B R; Lucarelli M R; Farag S S; Byrd J C; Copelan E A
Diffuse alveolar hemorrhage following gemtuzumab ozogamicin.
Bone marrow transplantation 2005;35(8):823-4.
-
2005: Farag S S; Bolwell B J; Elder P J; Kalaycio M; Lin T; Pohlman B; Penza S; Marcucci G; Blum W; Sobecks R; Avalos B R; Byrd J C; Copelan E
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Bone marrow transplantation 2005;35(7):653-61.
-
2005: Johnson Amy J; Smith Lisa L; Zhu Jiuxiang; Heerema Nyla A; Jefferson Sara; Mone Andrew; Grever Michael; Chen Ching-Shih; Byrd John C
A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
Blood 2005;105(6):2504-9.
-
2005: Liu Shujun; Shen Tiansheng; Huynh Lenguyen; Klisovic Marko I; Rush Laura J; Ford Jamie L; Yu Jianhua; Becknell Brian; Li Yu; Liu Chunhui; Vukosavljevic Tamara; Whitman Susan P; Chang Kun-Sang; Byrd John C; Perrotti Danilo; Plass Christoph; Marcucci Guido
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.
Cancer research 2005;65(4):1277-84.
-
2005: Byrd John C; Marcucci Guido; Parthun Mark R; Xiao Jim J; Klisovic Rebecca B; Moran Mollie; Lin Thomas S; Liu Shujun; Sklenar Amy R; Davis Melanie E; Lucas David M; Fischer Beth; Shank Roshini; Tejaswi Sooraj L; Binkley Philip; Wright John; Chan Kenneth K; Grever Michael R
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Blood 2005;105(3):959-67.
-
2005: Lin Thomas S; Flinn Ian W; Modali Rama; Lehman Teresa A; Webb Jennifer; Waymer Sharon; Moran Mollie E; Lucas Margaret S; Farag Sherif S; Byrd John C
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.
Blood 2005;105(1):289-91.
-
2005: Byrd John C; Rai Kanti; Peterson Bercedis L; Appelbaum Frederick R; Morrison Vicki A; Kolitz Jonathan E; Shepherd Lois; Hines John D; Schiffer Charles A; Larson Richard A
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Blood 2005;105(1):49-53.
-
2004: Blum Kristie A; Lozanski Gerard; Byrd John C
Adult Burkitt leukemia and lymphoma.
Blood 2004;104(10):3009-20.
-
2004: Eisenbeis Charles F; Grainger Andrew; Fischer Beth; Baiocchi Robert A; Carrodeguas Lester; Roychowdhury Sameek; Chen Lei; Banks Amy L; Davis Thomas; Young Donn; Kelbick Nicole; Stephens Julie; Byrd John C; Grever Michael R; Caligiuri Michael A; Porcu Pierluigi
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6101-10.
-
2004: Lin Thomas S; Moran Mollie; Lucas Margaret; Waymer Sharon; Jefferson Sara; Fischer Diane B; Grever Michael R; Byrd John C
Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
Hematology/oncology clinics of North America 2004;18(4):895-913, ix-x.
-
2004: Lucas D M; Davis M E; Parthun M R; Mone A P; Kitada S; Cunningham K D; Flax E L; Wickham J; Reed J C; Byrd J C; Grever M R
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(7):1207-14.
-
2004: Lozanski Gerard; Heerema Nyla A; Flinn Ian W; Smith Lisa; Harbison Jennifer; Webb Jennifer; Moran Mollie; Lucas Margaret; Lin Thomas; Hackbarth Marcy L; Proffitt John H; Lucas David; Grever Michael R; Byrd John C
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
Blood 2004;103(9):3278-81.
-
2004: Rush Laura J; Raval Aparna; Funchain Pauline; Johnson Amy J; Smith Lisa; Lucas David M; Bembea Melania; Liu Te-Hui; Heerema Nyla A; Rassenti Laura; Liyanarachchi Sandya; Davuluri Ramana; Byrd John C; Plass Christoph
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets.
Cancer research 2004;64(7):2424-33.
-
2004: Byrd John C; Ruppert Amy S; Mrózek Krzysztof; Carroll Andrew J; Edwards Colin G; Arthur Diane C; Pettenati Mark J; Stamberg Judith; Koduru Prasad R K; Moore Joseph O; Mayer Robert J; Davey Frederick R; Larson Richard A; Bloomfield Clara D
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1087-94.
-
2004: Mone Andrew P; Huang Peng; Pelicano Helene; Cheney Carolyn M; Green Jennifer M; Tso J Yun; Johnson Amy J; Jefferson Sara; Lin Thomas S; Byrd John C
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells.
Blood 2004;103(5):1846-54.
-
2004: Farag Sherif S; Flinn Ian W; Modali Rama; Lehman Teresa A; Young Donn; Byrd John C
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.
Blood 2004;103(4):1472-4.
-
2004: Lu Qiang; Yang Ya-Ting; Chen Chang-Shi; Davis Melanie; Byrd John C; Etherton Mark R; Umar Asad; Chen Ching-Shih
Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors.
Journal of medicinal chemistry 2004;47(2):467-74.
-
2004: Zhang Liwen; Freitas Michael A; Wickham Joseph; Parthun Mark R; Klisovic Marko I; Marcucci Guido; Byrd John C
Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry.
Journal of the American Society for Mass Spectrometry 2004;15(1):77-86.
-
2004: Byrd John C; Stilgenbauer Stephan; Flinn Ian W
Chronic lymphocytic leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2004;():163-83.
-
2004: Lin Thomas S; Byrd John C
Monoclonal antibody therapy in lymphoid leukemias.
Advances in pharmacology (San Diego, Calif.) 2004;51():127-67.
-
2004: Marcucci G; Stock W; Dai G; Klisovic M I; Maharry K; Shen T; Liu S; Sher D A; Lucas D; Zwiebel A; Larson R A; Caligiuri M A; Bloomfield C D; Chan K K; Grever M R; Byrd J C
G3139, a BCL-2 antisense oligo-nucleotide, in AML.
Annals of hematology 2004;83 Suppl 1():S93-4.
-
2004: Bloomfield C D; Ruppert A S; Mrózek K; Kolitz J E; Moore J O; Mayer R J; Edwards C G; Sterling L J; Vardiman J W; Carroll A J; Pettenati M J; Stamberg J; Byrd J C; Marcucci G; Larson R A;
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.
Annals of hematology 2004;83 Suppl 1():S84-5.
-
2003: Pavletic Steven Z; Bociek R Gregory; Foran James M; Rubocki Ronald J; Kuszynski Charles A; Wisecarver James L; Hatcher Lori; Lucas David M; Byrd John C; Grever Michael R; Joshi Shantaram S; Hardiman Penny; Smith Lynette M; McGuire Timothy R; Bierman Philip J; Vose Julie M; Armitage James O; Talmadge James E
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation.
Transplantation 2003;76(5):877-81.
-
2003: Lin Thomas S; Lucas Margaret S; Byrd John C
Rituximab in B-cell chronic lymphocytic leukemia.
Seminars in oncology 2003;30(4):483-92.
-
2003: Bains S K; Mone A; Yun Tso J; Lucas D; Byrd J C; Weiner G J; Green J M
Mitochondria control of cell death induced by anti-HLA-DR antibodies.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(7):1357-65.
-
2003: Johnson Amy J; Mone Andrew P; Abhyankar Vivek; Byrd John C
Advances in the therapy of chronic lymphocytic leukemia.
Current opinion in hematology 2003;10(4):297-305.
-
2003: Aron Jennifer L; Parthun Mark R; Marcucci Guido; Kitada Shinichi; Mone Andrew P; Davis Melanie E; Shen Tiansheng; Murphy Timothy; Wickham Joseph; Kanakry Chris; Lucas David M; Reed John C; Grever Michael R; Byrd John C
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Blood 2003;102(2):652-8.
-
2003: Kreiling Jodi L; Byrd James C; Deisz Robert J; Mizukami Ikuko F; Todd Robert F; MacDonald Richard G
Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPAR.
The Journal of biological chemistry 2003;278(23):20628-37.
-
2003: Byrd John C; Lucas David M; Mone Andrew P; Kitner Joshua B; Drabick Joseph J; Grever Michael R
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.
Blood 2003;101(11):4547-50.
-
2003: Bannerji Rajat; Kitada Shinichi; Flinn Ian W; Pearson Michael; Young Donn; Reed John C; Byrd John C
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1466-71.
-
2003: Schaffer Beverly S; Lin Ming-Fong; Byrd James C; Park Jung H Y; MacDonald Richard G
Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cells.
Endocrinology 2003;144(3):955-66.
-
2003: Klisovic M I; Maghraby E A; Parthun M R; Guimond M; Sklenar A R; Whitman S P; Chan K K; Murphy T; Anon J; Archer K J; Rush L J; Plass C; Grever M R; Byrd J C; Marcucci G
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(2):350-8.
-
2003: Byrd J C; Peterson B; Piro L; Saven A; Vardiman J W; Larson R A; Schiffer C
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(2):323-7.
-
2003: Byrd John C; Smith Lisa; Hackbarth Marcy L; Flinn Ian W; Young Donn; Proffitt John H; Heerema Nyla A
Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
Cancer research 2003;63(1):36-8.
-
2003: Marcucci Guido; Byrd John C; Dai Guowei; Klisovic Marko I; Kourlas Peter J; Young Donn C; Cataland Spero R; Fisher Diane B; Lucas David; Chan Kenneth K; Porcu Pierluigi; Lin Zhong-Pin; Farag Sherif F; Frankel Stanley R; Zwiebel James A; Kraut Eric H; Balcerzak Stanley P; Bloomfield Clara D; Grever Michael R; Caligiuri Michael A
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Blood 2003;101(2):425-32.
-
2003: Byrd John C; Peterson Bercedis L; Morrison Vicki A; Park Kathleen; Jacobson Robert; Hoke Eva; Vardiman James W; Rai Kanti; Schiffer Charles A; Larson Richard A
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
Blood 2003;101(1):6-14.
-
2003: Macdonald Richard G; Byrd James C
The insulin-like growth factor II/mannose 6-phosphate receptor: implications for IGF action in breast cancer.
Breast disease 2003;17():61-72.
-
2002: Byrd John C; Mrózek Krzysztof; Dodge Richard K; Carroll Andrew J; Edwards Colin G; Arthur Diane C; Pettenati Mark J; Patil Shivanand R; Rao Kathleen W; Watson Michael S; Koduru Prasad R K; Moore Joseph O; Stone Richard M; Mayer Robert J; Feldman Eric J; Davey Frederick R; Schiffer Charles A; Larson Richard A; Bloomfield Clara D;
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Blood 2002;100(13):4325-36.
-
2002: Helman Donald L; Byrd John C; Ales Noel C; Shorr Andrew F
Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.
Chest 2002;122(3):785-90.
-
2002: Drabick J J; Davis B J; Lichy J H; Flynn J; Byrd J C
Human herpesvirus 8 genome is not found in whole bone marrow core biopsy specimens of patients with plasma cell dyscrasias.
Annals of hematology 2002;81(6):304-7.
-
2002: Perkins Jeremy G; Flynn Joseph M; Howard Robin S; Byrd John C
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Cancer 2002;94(7):2033-9.
-
2002: Byrd John C; Kitada Shinichi; Flinn Ian W; Aron Jennifer L; Pearson Michael; Lucas David; Reed John C
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
Blood 2002;99(3):1038-43.
-
2001: Cataland S R; Lucas M; Byrd J C
Antibody therapy of acute and chronic leukemias.
Current pharmaceutical biotechnology 2001;2(4):357-67.
-
2001: Waselenko J K; Shinn C A; Willis C R; Flinn I W; Grever M R; Byrd J C
Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells.
Leukemia & lymphoma 2001;42(5):1049-53.
-
2001: Byrd J C; Shinn C; Willis C R; Flinn I W; Lehman T; Sausville E; Lucas D; Grever M R
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
Experimental hematology 2001;29(6):703-8.
-
2001: Waselenko J K; Grever M R; Shinn C A; Flinn I W; Byrd J C
Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia.
Leukemia research 2001;25(6):435-40.
-
2001: Treon S P; Agus T B; Link B; Rodrigues G; Molina A; Lacy M Q; Fisher D C; Emmanouilides C; Richards A I; Clark B; Lucas M S; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson K C; Byrd J C
CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(3):272-9.
-
2001: Drabick J J; Davis B J; Byrd J C
Concurrent pernicious anemia and myelodysplastic syndrome.
Annals of hematology 2001;80(4):243-5.
-
2001: Byrd J C; Murphy T; Howard R S; Lucas M S; Goodrich A; Park K; Pearson M; Waselenko J K; Ling G; Grever M R; Grillo-Lopez A J; Rosenberg J; Kunkel L; Flinn I W
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2153-64.
-
2000: Flynn J M; Byrd J C
Campath-1H monoclonal antibody therapy.
Current opinion in oncology 2000;12(6):574-81.
-
2000: Byrd J C; Waselenko J K; Keating M; Rai K; Grever M R
Novel therapies for chronic lymphocytic leukemia in the 21st century.
Seminars in oncology 2000;27(5):587-97.
-
2000: Flinn I W; Byrd J C; Morrison C; Jamison J; Diehl L F; Murphy T; Piantadosi S; Seifter E; Ambinder R F; Vogelsang G; Grever M R
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
Blood 2000;96(1):71-5.
-
2000: Byrd J C; Park J H; Schaffer B S; Garmroudi F; MacDonald R G
Dimerization of the insulin-like growth factor II/mannose 6-phosphate receptor.
The Journal of biological chemistry 2000;275(25):18647-56.
-
2000: Byrd J C; MacDonald R G
Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor.
The Journal of biological chemistry 2000;275(25):18638-46.
-
2000: Killian J K; Byrd J C; Jirtle J V; Munday B L; Stoskopf M K; MacDonald R G; Jirtle R L
M6P/IGF2R imprinting evolution in mammals.
Molecular cell 2000;5(4):707-16.
-
2000: Waselenko J K; Grever M R; Beer M; Lucas M A; Byrd J C
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Seminars in oncology 2000;27(2 Suppl 5):44-51.
-
2000: Byrd J C; Grever M R; Waselenko J K; Willis C R; Park K; Goodrich A; Lucas M A; Shinn C; Flinn I W
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.
Seminars in oncology 2000;27(2 Suppl 5):37-40.
-
2000: Bannerji R; Byrd J C
Update on the biology of chronic lymphocytic leukemia.
Current opinion in oncology 2000;12(1):22-9.
-
1999: Byrd J C; White C A; Link B; Lucas M S; Velasquez W S; Rosenberg J; Grillo-López A J
Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(12):1525-7.
-
1999: Byrd J C; Dodge R K; Carroll A; Baer M R; Edwards C; Stamberg J; Qumsiyeh M; Moore J O; Mayer R J; Davey F; Schiffer C A; Bloomfield C D
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(12):3767-75.
-
1999: McGrail L H; Sehn L H; Weiss R B; Robson M R; Antin J H; Byrd J C
Pancreatitis during therapy of acute myeloid leukemia: cytarabine related?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1373-6.
-
1999: Daniels J T; Davis B J; Houde-McGrail L; Byrd J C
Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biological marker?
British journal of haematology 1999;107(2):381-3.
-
1999: Devi G R; De Souza A T; Byrd J C; Jirtle R L; MacDonald R G
Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers.
Cancer research 1999;59(17):4314-9.
-
1999: Byrd J C; Devi G R; de Souza A T; Jirtle R L; MacDonald R G
Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations.
The Journal of biological chemistry 1999;274(34):24408-16.
-
1999: Byrd J C; Shinn C; Ravi R; Willis C R; Waselenko J K; Flinn I W; Dawson N A; Grever M R
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.
Blood 1999;94(4):1401-8.
-
1999: Byrd J C; McGrail L H; Hospenthal D R; Howard R S; Dow N A; Diehl L F
Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study.
British journal of haematology 1999;105(2):445-7.
-
1999: Byrd J C; Waselenko J K; Maneatis T J; Murphy T; Ward F T; Monahan B P; Sipe M A; Donegan S; White C A
Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):791-5.
-
1999: Murray C K; Estey E; Paietta E; Howard R S; Edenfield W J; Pierce S; Mann K P; Bolan C; Byrd J C
CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):293-7.
-
1998: Devi G R; Byrd J C; Slentz D H; MacDonald R G
An insulin-like growth factor II (IGF-II) affinity-enhancing domain localized within extracytoplasmic repeat 13 of the IGF-II/mannose 6-phosphate receptor.
Molecular endocrinology (Baltimore, Md.) 1998;12(11):1661-72.
-
1998: Byrd J C; Shinn C; Waselenko J K; Fuchs E J; Lehman T A; Nguyen P L; Flinn I W; Diehl L F; Sausville E; Grever M R
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Blood 1998;92(10):3804-16.
-
1998: Bloomfield C D; Lawrence D; Byrd J C; Carroll A; Pettenati M J; Tantravahi R; Patil S R; Davey F R; Berg D T; Schiffer C A; Arthur D C; Mayer R J
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Cancer research 1998;58(18):4173-9.
-
1998: Byrd J C; Lawrence D; Arthur D C; Pettenati M J; Tantravahi R; Qumsiyeh M; Stamberg J; Davey F R; Schiffer C A; Bloomfield C D
Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1235-41.
-
1998: Weiss R B; Freiman J; Kweder S L; Diehl L F; Byrd J C
Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1885-9.
-
1998: Wiesen A R; Byrd J C; Hospenthal D R; Howard R S; Shorr A R; Glass K L; Diehl L F
Transient abnormalities in serum bilirubin and lactate dehydrogenase levels following red blood cell transfusions in adults.
The American journal of medicine 1998;104(2):144-7.
-
1998: Byrd J C; Rai K R; Sausville E A; Grever M R
Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.
Seminars in oncology 1998;25(1):65-74.
-
1998: Byrd J C; Flinn I W; Grever M R
Introduction: chronic lymphocytic leukemia.
Seminars in oncology 1998;25(1):4-5.
-
1998: Vick D J; Byrd J C; Beal C L; Chaffin D J
Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma.
Vox sanguinis 1998;74(2):122-6.
-
1997: Shields D J; Byrd J C; Abbondanzo S L; Lichy J H; Diehl L F; Aguilera N I
Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1997;10(11):1151-9.
-
1997: Baer M R; Stewart C C; Lawrence D; Arthur D C; Byrd J C; Davey F R; Schiffer C A; Bloomfield C D
Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22).
Blood 1997;90(4):1643-8.
-
1997: Byrd J C; Dow N S; Gaertner E; Hargis J B; Raber T R; Burrell L; Weiss R B
Leukemic thyroiditis as the initial relapsing sign in a patient with acute lymphocytic leukemia and blast expression of the neural cell adhesion molecule.
American journal of hematology 1997;55(4):212-5.
-
1997: Byrd J C; Weiss R B; Arthur D C; Lawrence D; Baer M R; Davey F; Trikha E S; Carroll A J; Tantravahi R; Qumsiyeh M; Patil S R; Moore J O; Mayer R J; Schiffer C A; Bloomfield C D
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):466-75.
-
1996: Kester K E; Byrd J C; Rearden T P; Zacher L L; Cragun W H; Hargis J B
Granulomatous Pneumocystis carinii pneumonia in patients with low-grade lymphoid malignancies: a diagnostic dilemma.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;22(6):1111-2.
-
1996: McBride C E; Yavorski R T; Moses F M; Robson M E; Solimando D A; Byrd J C
Acute pancreatitis associated with continuous infusion cytarabine therapy: a case report.
Cancer 1996;77(12):2588-91.
-
1996: Alkins S A; Byrd J C; Morgan S K; Ward F T; Weiss R B
Anaphylactoid reactions to methotrexate.
Cancer 1996;77(10):2123-6.
-
1996: Byrd J C; Edenfield W J; Dow N S; Aylesworth C; Dawson N
Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia.
Leukemia & lymphoma 1996;21(1-2):153-9.
-
1995: Hospenthal D R; Byrd J C; Weiss R B
Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex.
Medical and pediatric oncology 1995;25(2):119-22.
-
1995: Byrd J C; Edenfield W J; Shields D J; Dawson N A
Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1800-16.
-
1995: Byrd J C; Hargis J B; Kester K E; Hospenthal D R; Knutson S W; Diehl L F
Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis.
American journal of hematology 1995;49(2):135-42.
-
1995: Byrd J C; Hertler A A; Weiss R B; Freiman J; Kweder S L; Diehl L F
Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(3):300-1.
-
1994: Wiesen A R; Hospenthal D R; Byrd J C; Glass K L; Howard R S; Diehl L F
Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding.
Annals of internal medicine 1994;121(4):278-30.
-
1994: Byrd J C; Weiss R B
Recurrent granulocytic sarcoma. An unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule.
Cancer 1994;73(8):2107-12.
Sign-in to see more
